We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Losartanis a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Losartan studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality randomised trials published 2001–2022 with a typical study size of 1,513 participants.
Based on 7 studies · 3 RCTs · 11,314 total participants
Confidence
ModerateBy outcome
Losartan has an evidence score of 4.2/10 — emerging evidence based on 7 indexed studies. An angiotensin-receptor blocker (Cozaar) — a first-line blood-pressure drug with proven human stroke-prevention and diabetic-kidney-protection outcomes. Its longevity/geroscience interest is the renin-angiotensin–aging axis plus a striking ANIMAL story: blocking the AT1 receptor dampens TGF-β signaling and restores muscle repair in aged/sarcopenic mice. But the anti-sarcopenia and lifespan benefits remain animal-only — not demonstrated in humans. A prescription drug used off-label, not a supplement. Representative study: PMID 11937178.
The commonly studied dose of Losartan is Off-label longevity/muscle-aging use mirrors low antihypertensive dosing (25–100 mg once daily) under a clinician. Not an approved longevity or anti-sarcopenia regimen; blood pressure, kidney function, and potassium should be monitored.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Nicotinamide Riboside
Mostly mechanism / observationalA vitamin B3 precursor that reliably raises cellular NAD+ levels and is well tolerated — but human trials have so far shown mostly null or mixed results on the functional outcomes (muscle, metabolism, blood pressure, cognition) that elevation is meant to drive.
MitoQ
Mostly mechanism / observationalLast reviewed June 2026 · evidence from 7 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Losartan (Cozaar) — angiotensin-receptor blocker (ARB)
An angiotensin-receptor blocker (Cozaar) — a first-line blood-pressure drug with proven human stroke-prevention and diabetic-kidney-protection outcomes. Its longevity/geroscience interest is the renin-angiotensin–aging axis plus a striking ANIMAL story: blocking the AT1 receptor dampens TGF-β signaling and restores muscle repair in aged/sarcopenic mice. But the anti-sarcopenia and lifespan benefits remain animal-only — not demonstrated in humans. A prescription drug used off-label, not a supplement.
Losartan has strong human outcome evidence as an antihypertensive — LIFE showed stroke reduction beyond atenolol and RENAAL showed diabetic-kidney protection — and an unusually concrete muscle-aging mechanism (AT1/TGF-β blockade restores muscle repair and protects against disuse atrophy in aged mice). But the anti-sarcopenia and longevity benefits are animal-only, no human trial shows it extends lifespan or prevents sarcopenia, and its own Marfan trial (losartan ≈ atenolol on aortic-root growth) shows mechanism doesn't guarantee outcome — so the geroprotector use stays emerging.
Losartan is the prototype angiotensin-receptor blocker (ARB) — it blocks the angiotensin II type-1 (AT1) receptor rather than inhibiting ACE, giving the renin-angiotensin (RAS) benefits of an ACE inhibitor without the bradykinin-mediated cough.
It is a first-line antihypertensive with deep, robust human outcome data: the landmark LIFE trial showed losartan reduced cardiovascular events — driven by a significant reduction in stroke — more than the beta-blocker atenolol at equal blood-pressure lowering, and the RENAAL trial showed it slowed progression of diabetic kidney disease to end-stage renal failure.
Those are the proven human benefits: blood pressure, stroke prevention, and renal protection. Its place in a longevity collection rests on two threads.
First, the RAS is a conserved aging axis (the same rationale as the ACE inhibitor captopril) — angiotensin II signaling drives inflammation, oxidative stress, fibrosis, and cellular senescence, and RAS modulation is repeatedly framed as a candidate geroprotective pathway.
Second, and more specifically, losartan has a striking muscle-aging story in animals: AT1-receptor blockade attenuates excess TGF-β signaling, and in mice this normalizes muscle regeneration in Marfan and Duchenne models (Cohn 2007) and restores muscle remodeling while protecting against disuse atrophy in sarcopenic aged mice (Burks 2011, via both TGF-β blockade and IGF-1/Akt/mTOR activation).
The honest distinction this collection insists on: those anti-sarcopenia and muscle-regeneration findings are animal-only, and there is no human trial showing losartan extends lifespan, prevents sarcopenia, or improves muscle function in older adults — the muscle-aging case is mechanistic and preclinical.
The best counter-evidence within the drug's own literature reinforces the limits of extrapolating from mechanism: in the pivotal pediatric Marfan trial (Lacro 2014), losartan did NOT slow aortic-root dilation more than atenolol despite the compelling TGF-β rationale — a reminder that a clean mechanism does not guarantee a clinical outcome.
Losartan is generally well tolerated (better than ACE inhibitors on cough); class effects are dizziness/hypotension, hyperkalemia, and a contraindication in pregnancy. It is a prescription drug used off-label for its proposed geroprotective/muscle-aging effects; it is not a dietary supplement.
The score reflects strong human cardiovascular/renal outcomes plus an unusually concrete (but animal-only) muscle-aging mechanism, against unproven human longevity or anti-sarcopenia benefit.
Losartan blocks the angiotensin II type-1 (AT1) receptor, lowering angiotensin II signaling — the renin-angiotensin axis that, beyond blood pressure, drives inflammation, oxidative stress, fibrosis, and senescence.
AT1 signaling amplifies TGF-β; blocking it dampens canonical (Smad2/3) and noncanonical TGF-β signaling, restoring satellite-cell function and muscle regeneration — shown in myopathic and aged-mouse muscle.
In aged mice, losartan protected against disuse atrophy partly by increasing IGF-1/Akt/mTOR signaling — a muscle-homeostasis pathway distinct from its TGF-β effect (Burks 2011).
How Losartan works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Off-label longevity/muscle-aging use mirrors low antihypertensive dosing (25–100 mg once daily) under a clinician. Not an approved longevity or anti-sarcopenia regimen; blood pressure, kidney function, and potassium should be monitored.
Can be taken without food
| Form | Type |
|---|---|
| 💊Oral tablet (losartan potassium) | Recommended |
| 💊Telmisartan / candesartan (other ARBs sharing the class effects) | Alternative |
Losartan is the prototype ARB; the muscle-aging animal evidence is losartan-specific, while the cardiovascular/renal class effects are shared across ARBs.
Minimum: 12 weeks
Optimal: 52 weeks
Cycling: Not required
Note: Once daily; monitor blood pressure, kidney function, and potassium. Antihypertensive effect builds over 3–6 weeks.
Dose-response data unavailable. The current published research for Losartan does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
LIFE showed losartan reduced cardiovascular events — driven by fewer strokes — beyond atenolol at equal blood-pressure lowering (human RCT).
RENAAL showed losartan slowed progression of type-2 diabetic nephropathy to end-stage renal disease (human RCT).
In aged/sarcopenic mice, losartan restored muscle remodeling and protected against disuse atrophy via TGF-β blockade and IGF-1/Akt/mTOR — not shown in humans.
Dizziness and first-dose hypotension, possible high potassium; contraindicated in pregnancy. Less cough than ACE inhibitors.
Contraindicated — ARBs cause fetal renal and developmental harm.
Monitor kidney function and potassium closely.
Caution — first-dose hypotension; correct dehydration first and start low.
Additive hyperkalemia risk — can be dangerous.
Reduce ARB effect and can worsen renal function (the 'triple whammy' with diuretics).
ARBs raise lithium levels and toxicity risk.
Tip: Most likely with the first dose, dehydration, or alongside diuretics; start low and rise slowly.
Tip: Monitor potassium; avoid potassium supplements/salt substitutes, especially in renal impairment.
Tip: Much rarer than with ACE inhibitors; stop immediately and seek care.
Timing is flexible for Losartan — consistent daily use matters more than the time of day. Once daily (sometimes split), with or without food.
Losartan should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are dizziness / hypotension, hyperkalemia, angioedema. Use caution if any of these apply to you: Pregnancy (fetal harm); Bilateral renal artery stenosis; Hyperkalemia.
A mitochondria-targeted antioxidant — CoQ10 conjugated to a triphenylphosphonium (TPP+) cation so it accumulates several-hundred-fold inside mitochondria. Sold OTC as a supplement. Its best human signal is improved endothelial/vascular function in older adults (one small RCT); several trials are null (Parkinson's, exercise adaptation), and almost all outcomes are surrogate/biomarker, not hard clinical endpoints.